Mesenchymal Stem Cells Enhance Chemotaxis of Activated T Cells Through the CCL2-CCR2 Axis In Vitro

Overview

Journal Bull Exp Biol Med

Publisher Springer

Specialty General Medicine

Date 2021 Dec 2

PMID 34855085

Citations 2

Authors

Y L Zhang

S K Qiao

L N Xing

X N Guo

J H Ren

Affiliations

Soon will be listed here.

Abstract

Activation and migration of donor T cells to the host target organs are critical mechanisms in the pathogenesis of graft-versus-host disease (GVHD). The role of monocyte chemoattractant protein-1 (MCP-1/CCL2) and its receptor CCR2 in the recruitment of T cells during immune or inflammatory response is also well known. For elucidation of the mechanism of the therapeutic effect of human bone marrow derived-mesenchymal stem cells (MSC) in GVHD, we studied the effect of these cells on migration of activated donor T cells through the CCL2-CCR2 axis in vitro. MSC were expanded from donors' bone marrow mononuclear cells. After co-culturing of IL-2-activated T cells with allogeneic MSC at different ratios, the levels of CCL2 in supernatants were measured by ELISA, and CCR2 expression in CD4/CD8 T cells subsets were detected by flow cytometry. The effect of MSC on the migration of activated T cells in the Transwell system was studied in the absence or presence of CCL2. Our results show that CCL2 levels in supernatants of co-cultures were significantly higher than in MSC monoculture and this increase depended on the number of MSC. MSC inhibited proliferation of T cells, but did not change the percentages of CD4 and CD8 T cells subsets. MSC can up-regulate the CCR2 expression in CD8 subsets rather than in CD4 subsets; MSC enhanced migration of IL-2-activated T cells to CCL2 by increasing the expression of CCR2. The data demonstrate that MSC can enhance chemotaxis of cytokine-activated T cells through the CCL2-CCR2 axis in vitro.

Citing Articles

Superior migration ability of umbilical cord-derived mesenchymal stromal cells (MSCs) toward activated lymphocytes in comparison with those of bone marrow and adipose-derived MSCs.

Hori A, Takahashi A, Miharu Y, Yamaguchi S, Sugita M, Mukai T Front Cell Dev Biol. 2024; 12:1329218.

PMID: 38529405 PMC: 10961348. DOI: 10.3389/fcell.2024.1329218.

Identification and validation of CCL2 as a potential biomarker relevant to mast cell infiltration in the testicular immune microenvironment of spermatogenic dysfunction.

Dong F, Ping P, Wang S, Ma Y, Chen X Cell Biosci. 2023; 13(1):94.

PMID: 37221631 PMC: 10204296. DOI: 10.1186/s13578-023-01034-2.

References

Abumaree M, Al Jumah M, Pace R, Kalionis B . Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev Rep. 2011; 8(2):375-92. DOI: 10.1007/s12015-011-9312-0. View

Baron F, Storb R . Mesenchymal stromal cells: a new tool against graft-versus-host disease?. Biol Blood Marrow Transplant. 2011; 18(6):822-40. PMC: 3310956. DOI: 10.1016/j.bbmt.2011.09.003. View

Blazar B, Murphy W, Abedi M . Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012; 12(6):443-58. PMC: 3552454. DOI: 10.1038/nri3212. View

Bradley L, Asensio V, Schioetz L, Harbertson J, Krahl T, Patstone G . Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol. 1999; 162(5):2511-20. View

CARR M, Roth S, Luther E, ROSE S, Springer T . Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A. 1994; 91(9):3652-6. PMC: 43639. DOI: 10.1073/pnas.91.9.3652. View

Daly C, Rollins B . Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation. 2003; 10(3-4):247-57. DOI: 10.1038/sj.mn.7800190. View

Flaishon L, Hart G, Zelman E, Moussion C, Grabovsky V, Lapidot Tal G . Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions. Blood. 2008; 112(13):5016-25. DOI: 10.1182/blood-2007-12-129122. View

Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R . In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol. 1997; 62(5):577-80. DOI: 10.1002/jlb.62.5.577. View

Hildebrandt G, Duffner U, Olkiewicz K, Corrion L, Willmarth N, Williams D . A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood. 2003; 103(6):2417-26. DOI: 10.1182/blood-2003-08-2708. View

10.

Kebriaei P, Robinson S . Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy. 2011; 13(3):262-8. DOI: 10.3109/14653249.2010.549688. View

11.

Moreno D, Cid J . Graft-versus-host disease. Med Clin (Barc). 2018; 152(1):22-28. DOI: 10.1016/j.medcli.2018.07.012. View

12.

Mushahary D, Spittler A, Kasper C, Weber V, Charwat V . Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 2017; 93(1):19-31. DOI: 10.1002/cyto.a.23242. View

13.

New J, Li B, Koh W, Ng H, Tan S, Yap E . T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002; 29(12):979-86. DOI: 10.1038/sj.bmt.1703563. View

14.

Panoskaltsis-Mortari A, Hermanson J, Taras E, Wangensteen O, Charo I, Rollins B . Post-BMT lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells. Am J Physiol Lung Cell Mol Physiol. 2003; 286(2):L284-92. DOI: 10.1152/ajplung.00154.2003. View

15.

Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E . Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008; 112(13):4991-8. DOI: 10.1182/blood-2008-07-166892. View

16.

Ramachandran V, Kolli S, Strowd L . Review of Graft-Versus-Host Disease. Dermatol Clin. 2019; 37(4):569-582. DOI: 10.1016/j.det.2019.05.014. View

17.

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

18.

Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T . Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2006; 109(1):228-34. DOI: 10.1182/blood-2006-02-002246. View

19.

Terwey T, Kim T, Kochman A, Hubbard V, Lu S, Zakrzewski J . CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005; 106(9):3322-30. PMC: 1895329. DOI: 10.1182/blood-2005-05-1860. View

20.

Tolar J, Villeneuve P, Keating A . Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther. 2011; 22(3):257-62. DOI: 10.1089/hum.2011.1104. View